TRIAL DATA

With 3 years of adjuvant therapy in KIT+ GIST patients', at 5-year analysis, GLIVEC provided1

92% OVERALL SURVIVAL
66% RECURRENCE-FREE SURVIVAL

LEARN MORE
Adjuvant Clinical Results

Download NEW 3 year adjuvant Clinical Results

In advance disease,
GLIVEC EXTENDED OVERALL SURVIVAL TO

57 MONTHS
FROM 10 MONTHS2,3

LEARN MORE